<p>GRAIL, Inc.（納斯達克代碼：GRAL - 獲取免費報告）週一股價下跌 4%，原因是公司內部人士出售了該公司的股票。該公司股價最低曾達到 60.02 美元，最後交易價格為 62.95 美元。在交易過程中，約有 494,947 股成交，較日均成交量 1,277,161 股下降了 61%。該股票此前收盤價為 65.55 美元。</p>
<ul>
<li>2025 年表現優於市場的 3 只醫療科技股票</li>
</ul>
<p>具體來説，首席執行官 Joshua J. Ofman 在 10 月 2 日星期四出售了 9,692 股公司的股票。股票的平均售價為 64.00 美元，總價值為 620,288.00 美元。交易後，首席執行官直接持有 478,182 股公司股票，價值 30,603,648 美元。這筆交易使其持股比例減少了 1.99%。該交易已在提交給證券交易委員會的文件中披露，相關文件可通過此鏈接查看。</p>
<h2>分析師評級變動</h2>
<p>幾位股票分析師最近對該股票發表了評論。Weiss Ratings 在 9 月 27 日星期六的研究報告中重申了對 GRAIL 股票的 “賣出（d-）” 評級。Canaccord Genuity Group 將 GRAIL 股票的目標價從 43.00 美元上調至 75.00 美元，並在週五的研究報告中給予該股票 “買入” 評級。最後，瑞銀集團在週五的研究報告中設定了 GRAIL 股票的 75.00 美元目標價。一位投資分析師給予該股票 “買入” 評級，三位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 56.67 美元。</p>
<ul>
<li>GRAIL：瞄準 1000 億美元癌症市場的生物科技股票</li>
</ul>
<p><strong>閲讀我們對 GRAIL 的最新股票分析</strong></p>
<h2>GRAIL 股價下跌 3.5%</h2>
<p>該公司的 50 日移動平均線為 38.69 美元，200 日移動平均線為 37.25 美元。該公司的市值為 22.8 億美元，市盈率為-4.82，貝塔值為 4.11。</p>
<ul>
<li>戰略性買入點燃這隻生物科技股票：是時候投資了嗎？</li>
</ul>
<p>GRAIL（納斯達克代碼：GRAL - 獲取免費報告）最近一次發佈季度財報是在 8 月 12 日星期二。該公司報告每股收益（EPS）為-3.18 美元，低於市場共識預期的-3.14 美元，差距為 0.04 美元。GRAIL 的淨利潤率為-329.86%，股本回報率為-16.64%。該公司在本季度的收入為 3,554 萬美元，而分析師預期為 3,757 萬美元。分析師預測 GRAIL, Inc.在當前財年將發佈-15.15 的每股收益。</p>
<h2>GRAIL 的機構交易</h2>
<p>對沖基金最近買入和賣出了該公司的股票。Caldwell Sutter Capital Inc.在第一季度新建了 28,000 美元的 GRAIL 頭寸。KBC Group NV 在第一季度將其在 GRAIL 的持股增加了 187.7%。KBC Group NV 目前持有 1,430 股公司股票，價值 37,000 美元，此前在上個季度增持了 933 股。S.A. Mason LLC 在第一季度將其在 GRAIL 的持股增加了 50.1%。S.A. Mason LLC 目前持有 1,499 股公司股票，價值 38,000 美元，此前在上個季度增持了 500 股。Farther Finance Advisors LLC 在第二季度將其在 GRAIL 的持股增加了 768.1%。Farther Finance Advisors LLC 目前持有 816 股公司股票，價值 42,000 美元，此前在上個季度增持了 722 股。最後，NewEdge Advisors LLC 在第一季度將其在 GRAIL 的持股增加了 390.3%。NewEdge Advisors LLC 目前持有 1,760 股公司股票，價值 45,000 美元，此前在上個季度增持了 1,401 股。</p>
<h2>關於 GRAIL</h2>
<p>（獲取免費報告）</p>
<p>GRAIL, Inc.是一家商業階段的醫療保健公司，專注於開發早期癌症檢測技術。它利用機器學習、軟件和自動化技術在早期階段檢測和識別多種致命癌症類型。該公司由 Jeffrey T.創立。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 GRAIL 更具吸引力</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>進入假期前需要關注的 3 只旅遊股票</li>
<li>3 只引領迷因股票復甦的股票</li>
<li>15 美元以下的最佳股票？3 只低價潛力股</li>
<li>如何開始投資於便士股票</li>
<li>D-Wave 的巨大一週背後（以及為什麼競爭對手也上漲）</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 GRAIL 嗎？</h2>
<p>在考慮 GRAIL 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 GRAIL 並不在名單上。</p>
<p>雖然 GRAIL 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>查看這五隻股票</p>

GRAL

<p>GRAIL, Inc.（納斯達克代碼：GRAL）股價下跌 4%，原因是總裁 Joshua J. Ofman 出售了 9,692 股，售價為每股 64.00 美元。該股最低交易價為 60.02 美元，收盤價為 62.95 美元，交易量較平均水平下降了 61%。分析師的評級不一，包含一項買入、三項持有和一項賣出，目標價共識為 56.67 美元。GRAIL 報告季度每股虧損 3.18 美元，未達到預期，市值為 22.8 億美元</p>

<p>GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) shares were down 4% on Monday after an insider sold shares in the company. The company traded as low as $60.02 and last traded at $62.95. Approximately 494,947 shares traded hands during trading, a decline of 61% from the average daily volume of 1,277,161 shares. The stock had previously closed at $65.55.</p>
<div class="lb-trans"><p>GRAIL, Inc.（納斯達克代碼：GRAL - 獲取免費報告）週一股價下跌 4%，原因是公司內部人士出售了該公司的股票。該公司股價最低曾達到 60.02 美元，最後交易價格為 62.95 美元。在交易過程中，約有 494,947 股成交，較日均成交量 1,277,161 股下降了 61%。該股票此前收盤價為 65.55 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表現優於市場的 3 只醫療科技股票</li>
</ul>
</div><p>Specifically, President Joshua J. Ofman sold 9,692 shares of the company's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $64.00, for a total value of $620,288.00. Following the transaction, the president directly owned 478,182 shares in the company, valued at $30,603,648. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p>
<div class="lb-trans"><p>具體來説，首席執行官 Joshua J. Ofman 在 10 月 2 日星期四出售了 9,692 股公司的股票。股票的平均售價為 64.00 美元，總價值為 620,288.00 美元。交易後，首席執行官直接持有 478,182 股公司股票，價值 30,603,648 美元。這筆交易使其持股比例減少了 1.99%。該交易已在提交給證券交易委員會的文件中披露，相關文件可通過此鏈接查看。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several equities analysts recently commented on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of GRAIL in a research note on Saturday, September 27th. Canaccord Genuity Group increased their price objective on shares of GRAIL from $43.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday. Finally, UBS Group set a $75.00 price objective on shares of GRAIL in a research note on Friday. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus target price of $56.67.</p>
<div class="lb-trans"><p>幾位股票分析師最近對該股票發表了評論。Weiss Ratings 在 9 月 27 日星期六的研究報告中重申了對 GRAIL 股票的 “賣出（d-）” 評級。Canaccord Genuity Group 將 GRAIL 股票的目標價從 43.00 美元上調至 75.00 美元，並在週五的研究報告中給予該股票 “買入” 評級。最後，瑞銀集團在週五的研究報告中設定了 GRAIL 股票的 75.00 美元目標價。一位投資分析師給予該股票 “買入” 評級，三位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 56.67 美元。</p>
</div><ul>
<li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li>
</ul>
<div class="lb-trans"><ul>
<li>GRAIL：瞄準 1000 億美元癌症市場的生物科技股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on GRAIL</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 GRAIL 的最新股票分析</strong></p>
</div><h2>GRAIL Trading Down 3.5%</h2>
<div class="lb-trans"><h2>GRAIL 股價下跌 3.5%</h2>
</div><p>The firm's 50-day moving average is $38.69 and its 200-day moving average is $37.25. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -4.82 and a beta of 4.11.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 38.69 美元，200 日移動平均線為 37.25 美元。該公司的市值為 22.8 億美元，市盈率為-4.82，貝塔值為 4.11。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>戰略性買入點燃這隻生物科技股票：是時候投資了嗎？</li>
</ul>
</div><p>GRAIL (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The business had revenue of $35.54 million during the quarter, compared to analyst estimates of $37.57 million. Analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>GRAIL（納斯達克代碼：GRAL - 獲取免費報告）最近一次發佈季度財報是在 8 月 12 日星期二。該公司報告每股收益（EPS）為-3.18 美元，低於市場共識預期的-3.14 美元，差距為 0.04 美元。GRAIL 的淨利潤率為-329.86%，股本回報率為-16.64%。該公司在本季度的收入為 3,554 萬美元，而分析師預期為 3,757 萬美元。分析師預測 GRAIL, Inc.在當前財年將發佈-15.15 的每股收益。</p>
</div><h2>Institutional Trading of GRAIL</h2>
<div class="lb-trans"><h2>GRAIL 的機構交易</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Caldwell Sutter Capital Inc. bought a new position in GRAIL during the 1st quarter valued at $28,000. KBC Group NV lifted its stake in GRAIL by 187.7% during the 1st quarter. KBC Group NV now owns 1,430 shares of the company's stock valued at $37,000 after acquiring an additional 933 shares in the last quarter. S.A. Mason LLC lifted its stake in GRAIL by 50.1% during the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company's stock valued at $38,000 after acquiring an additional 500 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company's stock valued at $42,000 after acquiring an additional 722 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock valued at $45,000 after acquiring an additional 1,401 shares in the last quarter.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該公司的股票。Caldwell Sutter Capital Inc.在第一季度新建了 28,000 美元的 GRAIL 頭寸。KBC Group NV 在第一季度將其在 GRAIL 的持股增加了 187.7%。KBC Group NV 目前持有 1,430 股公司股票，價值 37,000 美元，此前在上個季度增持了 933 股。S.A. Mason LLC 在第一季度將其在 GRAIL 的持股增加了 50.1%。S.A. Mason LLC 目前持有 1,499 股公司股票，價值 38,000 美元，此前在上個季度增持了 500 股。Farther Finance Advisors LLC 在第二季度將其在 GRAIL 的持股增加了 768.1%。Farther Finance Advisors LLC 目前持有 816 股公司股票，價值 42,000 美元，此前在上個季度增持了 722 股。最後，NewEdge Advisors LLC 在第一季度將其在 GRAIL 的持股增加了 390.3%。NewEdge Advisors LLC 目前持有 1,760 股公司股票，價值 45,000 美元，此前在上個季度增持了 1,401 股。</p>
</div><h2>About GRAIL</h2>
<div class="lb-trans"><h2>關於 GRAIL</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.</p>
<div class="lb-trans"><p>GRAIL, Inc.是一家商業階段的醫療保健公司，專注於開發早期癌症檢測技術。它利用機器學習、軟件和自動化技術在早期階段檢測和識別多種致命癌症類型。該公司由 Jeffrey T.創立。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than GRAIL</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>3 Travel Stocks to Watch Heading Into the Holidays</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Best Stocks Under $15? 3 Low-Priced Picks With Upside</li>
<li>How to start investing in penny stocks</li>
<li>Behind D-Wave's Massive Week (And Why Rivals Also Popped)</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 GRAIL 更具吸引力</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>進入假期前需要關注的 3 只旅遊股票</li>
<li>3 只引領迷因股票復甦的股票</li>
<li>15 美元以下的最佳股票？3 只低價潛力股</li>
<li>如何開始投資於便士股票</li>
<li>D-Wave 的巨大一週背後（以及為什麼競爭對手也上漲）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GRAIL Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 GRAIL 嗎？</h2>
</div><p>Before you consider GRAIL, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 GRAIL 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 GRAIL 並不在名單上。</p>
</div><p>While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 GRAIL 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

GRAIL（納斯達克股票代碼：GRAL）在內部人士出售股票後股價下跌 4%